drugset

drugset / Trial / NCT00427583

Imatinib Mesylate Treatment of Patients With Malignant Peripheral Nerve Sheath Tumors

NCT00427583 ↗

Phase 2/3 Terminated 11 enrolled Novartis Pharmaceuticals

NaSingle-groupOpen-labelTreatment

Summary

This study assesses the safety and efficacy of imatinib mesylate treatment of patients with malignant peripheral nerve sheath tumors

Timeline

Start: 2006-05
Primary completion: 2009-04
Completion: —

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Imatinib	Small molecule	—	—

Indications